Amundi’s Beam Therapeutics BEAM Stock Holding History

Amundi’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,041	Closed	-$50.1K	–	1715
2025 Q1	$50.1K	Hold	3,041	–	–	﹤0.01%	1818
2024 Q4	$81.5K	Hold	3,041	–	–	﹤0.01%	1813
2024 Q3	$70.7K	Hold	3,041	–	–	﹤0.01%	1810
2024 Q2	$71.4K	Sell	3,041 -1,280	-30%	-$31.4K	﹤0.01%	1749
2024 Q1	$105K	Sell	4,321 -2,845	-40%	-$88.6K	﹤0.01%	1757
2023 Q4	$200K	Hold	7,166	–	–	﹤0.01%	1632
2023 Q3	$160K	Hold	7,166	–	–	﹤0.01%	1653
2023 Q2	$229K	Buy	7,166 +4,543	+173%	+$147K	﹤0.01%	1567
2023 Q1	$76.9K	Sell	2,623 -1,039	-28%	-$41K	﹤0.01%	1808
2022 Q4	$150K	Buy	3,662 +753	+26%	+$33.7K	﹤0.01%	1552
2022 Q3	$148K	Hold	2,909	–	–	﹤0.01%	1499
2022 Q2	$163K	Buy	2,909 +654	+29%	+$26K	﹤0.01%	1387
2022 Q1	$120K	Hold	2,255	–	–	﹤0.01%	1447
2021 Q4	$149K	Buy	2,255 +1,304	+137%	+$112K	﹤0.01%	1516
2021 Q3	$83K	Buy	+951	New	+$95.5K	﹤0.01%	1519

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Amundi's BEAM Position: Q2 2025 in Review

Amundi sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 3,041 shares — an estimated $50.1K sold.

Amundi first reported a position in BEAM in Q3 2021 and held it in 15 quarters. The position peaked at $229K in Q2 2023. 217 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

Amundi reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
Amundi sold 3,041 Beam Therapeutics shares in Q2 2025, an estimated $50.1K.
Amundi first reported a position in Beam Therapeutics in Q3 2021 and held it in 15 quarters.
Amundi's Beam Therapeutics position peaked at $229K in Q2 2023.
217 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.